Improvement of depressive behaviors by nefiracetam is associated with activation of CaM kinases in olfactory bulbectomized mice

Brain Research

Volumn 1265, Issue , 2009, Pages 205-214

  Han, Feng ^a,b   Nakano, Tetsuo ^a   Yamamoto, Yui ^a   Shioda, Norifumi ^a   Lu, Ying Mei ^a   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

CaMKII; CREB; Nefiracetam (DM 9384); NMDA; Olfactory bulbectomy

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CALPAIN 2; MITOGEN ACTIVATED PROTEIN KINASE; NEFIRACETAM; PROTEIN KINASE C;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; EXPERIMENTAL MOUSE; HIPPOCAMPUS; MOUSE; NONHUMAN; OLFACTORY CORTEX; PRIORITY JOURNAL;

AMYGDALA; ANALYSIS OF VARIANCE; ANIMALS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 1; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 4; DEPRESSION; HIPPOCAMPUS; IMMUNOBLOTTING; INJECTIONS, INTRAPERITONEAL; MALE; MAZE LEARNING; MEMORY; MICE; MICE, INBRED STRAINS; NOOTROPIC AGENTS; OLFACTORY BULB; PHOSPHORYLATION; PYRROLIDINONES; STRESS, PHYSIOLOGICAL; SWIMMING;

MUS;

EID: 62949198758     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.02.014     Document Type: Article

References (71)

1. Agid Y., Buzsáki G., Diamond D.M., Frackowiak R., Giedd J., Girault J.A., Grace A., Lambert J.J., Manji H., Mayberg H., Popoli M., Prochiantz A., Richter-Levin G., Somogyi P., Spedding M., Svenningsson P., and Weinberger D. How can drug discovery for psychiatric disorders be improved?. Nat. Rev. Drug. Discov. 6 (2007) 189-201
2. Ando T., Takagi N., Takagi K., Kago T., and Takeo S. Effects of nefiracetam on the levels of brain-derived neurotrophic factor and synapsin I mRNA and protein in the hippocampus of microsphere-embolized rats. Eur. J. Pharmacol. 507 (2005) 49-56
3. Consogno E., Racagni G., and Popoli M. Modifications in brain CaM kinase II after long-term treatment with desmethylimipramine. Neuropsychopharmacology 24 (2001) 21-30
4. DeFord S.M., Wilson M.S., Gibson C.J., Baranova A., and Hamm R.J. Nefiracetam improves Morris water maze performance following traumatic brain injury in rats. Pharmacol. Biochem. Behav. 69 (2001) 611-616
5. Dowlatshahi D., MacQueen G.M., Wang J.F., and Young L.T. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet 352 (1998) 1754-1755
6. D'Sa C., and Duman R.S. Antidepressants and neuroplasticity. Bipolar Disord. 4 (2002) 183-194
7. Du J., Szabo S.T., Gray N.A., and Manji H.K. Focus on CaMKII: a molecular switch in the pathophysiology and treatment of mood and anxiety disorders. Int. J. Neuropsychopharmacol. 7 (2004) 243-248
8. Dwivedi Y., Rizavi H.S., Roberts R.C., Conley R.C., Tamminga C.A., and Pandey G.N. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J. Neurochem. 77 (2001) 916-928
9. Dwivedi Y., Rizavi H.S., Conley R.R., and Pandey G.N. ERK MAP kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream Raf kinases Raf-1 and B-Raf. Mol. Psychiatry. 11 (2006) 86-98
10. 2+/calmodulin-dependent protein kinase IV. Role in transcriptional regulation. J. Biol. Chem. 269 (1994) 15520-15527
11. 2+/calmodulin-dependent protein kinase II in rat brain and various tissues. J. Neurochem. 51 (1988) 1070-1078
12. 2+/calmodulin-dependent protein kinase II-dependent long-term potentiation in the rat suprachiasmatic nucleus and its inhibition by melatonin. J. Neurosci. Res. 70 (2002) 799-807
13. Gorka Z., Earley B., and Leonard B.E. Effect of bilateral olfactory bulbectomy in the rat, alone or in combination with antidepressants, on the learned immobility model of depression. Neuropsychobiology 13 (1985) 26-30
14. Gurevich E.V., Aleksandrova I.A., Otmakhova N.A., Katkov Y.A., Nesterova I.V., and Bobkova N.V. Effects of bulbectomy and subsequent antidepressant treatment on brain 5-HT2 and 5-HT1A receptors in mice. Pharmacol. Biochem. Behav. 45 (1993) 65-70
15. Han F., Shioda N., Moriguchi S., Qin Z.H., and Fukunaga K. The vanadium (IV) compound rescues septo-hippocampal cholinergic neurons from neurodegeneration in olfactory bulbectomized mice. Neuroscience 151 (2008) 671-679
16. Hashimoto K., Shimizu E., and Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res. Brain Res. Rev. 45 (2004) 104-114
17. Hetman M., Kanning K., Cavanaugh J.E., and Xia Z. Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. J. Biol. Chem. 274 (1999) 22569-22580
18. Hozumi S., Nakagawasai O., Tan-No K., Niijima F., Yamadera F., Murata A., Arai Y., Yasuhara H., and Tadano T. Characteristics of changes in cholinergic function and impairment of learning and memory-related behavior induced by olfactory bulbectomy. Behav. Brain Res. 138 (2003) 9-15
19. Huang C.S., Ma J.Y., Marszalec W., and Narahashi T. Effects of the nootropic drug nefiracetam on the GABAA receptor-channel complex in dorsal root ganglion neurons. Neuropharmadology 35 (1996) 1251-1261
20. Johannessen M., Delghandi M.P., and Moens U. What turns CREB on?. Cell. Signal. 16 (2004) 1211-1227
21. 2+/calmodulin-dependent protein kinases in cultured rat hippocampal neurons. J. Biol. Chem. 274 (1999) 9061-9067
22. Kornhauser J.M., Cowan C.W., Shaywitz A.J., Dolmetsch R.E., Griffith E.C., Hu L.S., Haddad C., Xia Z., and Greenberg M.E. CREB transcriptional activity in neurons is regulated by multiple, calcium-specific phosphorylation events. Neurons 34 (2002) 221-233
23. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
24. Malberg J.E., and Blendy J.A. Antidepressant action: to the nucleus and beyond. Trends Pharmacol. Sci. 26 (2005) 631-638
25. Mathew S.J., Manji H.K., and Charney D.S. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 33 (2008) 2080-2092
26. Matthews R.P., Guthrie C.R., Wailes L.M., Zhao X., Means A.R., and McKnight G.S. Calcium/calmodulin-dependent protein kinase types II and IV differentially regulate CREB-dependent gene expression. Mol. Cell. Biol. 14 (1994) 6107-6116
27. McClung C.A., and Nestler E.J. Neuroplasticity mediated by altered gene expression. Neuropsychopharmacology 33 (2008) 3-17
28. Moriguchi S., Marszalec W., Zhao X., Yen J.Z., and Narahashi T. Potentiation of N-methyl-d-aspartate induced currents by the nootropic drug nefiracetam in rat cortical neurons. J. Pharmacol. Exp. Ther. 307 (2003) 160-167
29. Moriguchi S., Han F., Nakagawasai O., Tadano T., and Fukunaga K. Decreased calcium/calmoculin-dependent protein kinase II and protein kinase C activities mediate impairment of hippocampal long-term potentiation in the olfactory bulbectomized mice. J. Neurochem. 97 (2006) 22-29
30. Mucignat-Caretta C., Bondí M., and Caretta A. Time course of alterations after olfactory bulbectomy in mice. Physiol. Behav. 89 (2006) 637-643
31. Nakajima A., Yamakuni T., Haraguchi M., Omae N., Song S.Y., Kato C., Nakagawasai O., Tadano T., Yokosuka A., Mimaki Y., Sashida Y., and Ohizumi Y. Nobiletin, a citrus flavonoid that improves memory impairment, rescues bulbectomy-induced cholinergic neurodegeneration in mice. J. Pharmacol. Sci. 105 (2007) 122-126
32. Nestler E.J., Barrot M., Dileone R.J., Eisch A.J., Gold S.J., and Monteggia L.M. Neurobiology of depression. Neuron 34 (2002) 13-25
33. Nibuya M., Morinobu M., and Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatment. J. Neurosci. 15 (1995) 7539-7547
34. Nibuya M., Nestler E.J., and Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein in rat hippocampus. J. Neurosci. 16 (1996) 2365-2372
35. Nishizaki T., Nomura T., Matuoka T., Kondoh T., Enikolopo G., Sumikawa K., Watabe S., Shiotani T., and Yoshii M. The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors. Brain Res. Mol. Brain Res. 80 (2000) 53-62
36. Otmakhova N.A., Gurevich E.V., Katkov Y.A., Nesterova I.V., and Bobkova N.V. Dissociation of multiple behavioral effects between olfactory bulbectomized C57Bl/6J and DBA/2J mice. Physiol. Behav. 52 (1992) 441-448
37. Picciotto M.R., Zoli M., Bertuzzi G., and Nairn A.C. Immunochemical localization of calcium/calmodulin-dependent protein kinase I. Synapse 20 (1995) 75-84
38. Pittenger C., and Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33 (2008) 88-109
39. 2+/calmodulin-dependent protein kinase II: autophosphorylation and activity increase in the hippocampus after long-term blockade of serotonin reuptake. Mol. Pharmacol. 48 (1995) 623-629
40. Popoli M., Brunello N., Perez J., and Racagni G. Second messenger-regulated protein kinases in the brain: their function role and the action of antidepressant drugs. J. Neurochem. 74 (2000) 21-33
41. Popoli M., Gennarelli M., and Racagni G. Modulation of synaptic plasticity by stress and antidepressants. Bipolar Disord. 4 (2002) 166-182
42. Porsolt R.D., Pichon M.L., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266 (1977) 730-732
43. Robichaud M., Beauchemin V., Lavoie N., Dennis T., and Debonnel G. Effects of bilateral olfactory bulbectomy on N-methyl-d-aspartate receptor function: autoradiographic and behavioral studies in the rat. Synapse 42 (2001) 95-103
44. Ruhé H.G., Huyser J., Swinkels J.A., and Schene A.H. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J. Clin. Psychiatry 67 (2006) 1836-1855
45. 2+/calmodulin-dependent protein kinase IV and its expression confined to the mature cerebellar granule cells. Brain Res. Mol. Brain Res. 19 (1993) 215-218
46. Sakurai T., Kato T., Mori K., Takano E., Watabe S., and Nabeshima T. Nefiracetam elevates extracellular acetylcholine level in the frontal cortex of rats with cerebral cholinergic dysfunctions: an in vivo microdialysis study. Neurosci. Lett. 24, 246 (1998) 69-72
47. Segal R.A., and Greenberg M.E. Intracellular signaling pathways activated by neurotrophic factors. Annu. Rev. Neurosci. 19 (1996) 463-489
48. Schloss P., and Henn F.A. New insights into the mechanisms of antidepressant therapy. Pharmacol. Ther. 102 (2004) 47-60
49. Schüle C. Neuroendocrinological mechanisms of actions of antidepressant drugs. J. Neuroendocrinol. 19 (2007) 213-226
50. Sheng M., Thompson M.A., and Greenberg M.E. CREB: a Ca(2+)-regulated transcription factor phosphorylated by calmodulin-dependent kinases. Science 252 (1991) 1427-1430
51. Slotkin T.A., Miller D.B., Fumagalli F., McCook E.C., Zhang J., Bissette G., and Seidler F.J. Modeling geriatric depression in animals: biochemical and behavioral effects of olfactory bulbectomy in young versus aged rat. J. Pharmacol. Exp. Ther. 289 (1999) 334-345
52. Song C., and Leonard B.E. The olfactory bulbectomised rat as a model of depression. Neurosci. Biobehav. Rev. 29 (2005) 627-647
53. Steru L., Chermat R., Thierry B., and Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85 (1985) 367-370
54. 2+/calmodulin-dependent protein kinases type II and type IV involves phosphorylation of a site that negatively regulates activity. Genes Dev. 8 (1994) 2527-2539
55. 2+/calmodulin-dependent protein kinases type I, II, and IV. J. Biol. Chem. 271 (1996) 3066-3073
56. Tadano T., Hozumi S., Yamadera F., Murata A., Niijima F., Tanno K., Nakagawasai O., and Kisara K. Effects of NMDA receptor-related agonists on learning and memory impairment in olfactory bulbectomized mice. Methods Find. Exp. Clin. Pharmacol. 26 (2004) 93-97
57. Takeo S., Niimura M., Miyake-Takagi K., Nagakura A., Fukatsu T., Ando T., Takagi N., Tanonaka K., and Hara J. A possible mechanism for improvement by a cognition-enhancer nefiracetam of spatial memory function and cAMP-mediated signal transduction system in sustained cerebral ischaemia in rats. Br. J. Pharmacol. 138 (2003) 642-654
58. Tani Y., Kataoka Y., Sakurai Y., Yamashita K., Ushio M., and Ueki S. Changes of brain monoamine contents in three models of experimentally induced muricide in rats. Pharmacol. Biochem. Behav. 26 (1987) 725-729
59. Tardito D., Perez J., Tiraboschi E., Musazzi L., Racagni G., and Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol. Rev. 58 (2006) 115-134
60. Thome J., Sakai N., Shin K.H., Zhang Y.J., Impey S., Storm D., and Duman R.S. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J. Neurosci. 20 (2000) 4030-4036
61. Tiraboschi E., Giambelli R., D'Urso G., Galietta A., Barbon A., de Bartolomeis A., Gennarelli M., Barlati S., Racagni G., and Popoli M. Antidepressants activate CaMKII in neuron cell body by Thr286 phosphorylation. NeuroReport 15 (2004) 2393-2396
62. Tiraboschi E., Tardito D., Kasahara J., Moraschi S., Pruneri P., Gennarelli M., Racagni G., and Popoli M. Selective phosphorylation of nuclear CREB by fluoxetine is linked to activation of CaM kinase IV and MAP kinase cascades. Neuropsychopharmacology 29 (2004) 1831-1840
63. 2+/calmodulin-dependent protein kinase I in cultured rat hippocampal neurons. J. Neurochem. 82 (2002) 585-593
64. van der Stelt H.M., Breuer M.E., Olivier B., and Westenberg H.G. Permanent deficits in serotonergic functioning of olfactory bulbectomized rats: an in vivo microdialysis study. Biol. Psychiatry 57 (2005) 1061-1067
65. Wu X., and McMurray C.T. Calmodulin kinase II attenuation of gene transcription by preventing cAMP response element-binding protein (CREB) dimerization and binding of the CREB-binding protein. J. Biol. Chem. 276 (2001) 1735-1741
66. Xing G., Russell S., Hough C., O'Grady J., Zhang L., Yang S., Zhang L.X., and Post R. Decreased prefrontal CaMKII α mRNA in bipolar illness. NeuroReport 13 (2002) 501-505
67. Yamada K., Tanaka T., Mamiya T., Shiotani T., Kameyama T., and Nabeshima T. Improvement by nefiracetam of beta-amyloid-(1-42)-induced learning and memory impairments in rats. Br. J. Pharmacol. 126 (1999) 235-244
68. Yamada S., Yamamoto M., Ozawa H., Riederer P., and Saito T. Reduced phosphorylation of cyclic AMP-responsive element binding protein in the postmortem orbitofrontal cortex of patients with major depressive disorder. J. Neural. Transm. 110 (2003) 671-680
69. Yamamoto T., Jin J., and Watanabe S. Characteristics of memory dysfunction in olfactory bulbectomized rats and the effects of cholinergic drugs. Behav. Brain Res. 83 (1997) 57-62
70. Yan Y., Mizuno T., Nitta A., Yamada K., and Nabeshima T. Nefiracetam attenuates methamphetamine-induced discriminative stimulus effects in rats. Ann. N.Y. Acad. Sci. 1025 (2004) 274-278
71. Zhao X., Kuryatov A., Lindstrom M.J., Yen Z.J., and Narahashi T. Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons. Mol. Pharmacol. 59 (2001) 674-683